Lin W, Garnett M C, Davis S S, Schacht E, Ferruti P, Illum L
Department of Pharmaceutical Sciences, University of Nottingham, University Park, NG7 2RD, Nottingham, UK.
J Control Release. 2001 Mar 12;71(1):117-26. doi: 10.1016/s0168-3659(01)00209-7.
Surface-modified albumin nanoparticles were prepared from two poly(ethylene glycol)-human serum albumin conjugates: poly(thioetheramido acid)-poly(ethylene glycol) copolymer-grafted HSA (HSA-PTAAC-PEG) and methoxy poly(ethylene glycol)-grafted HSA (HSA-mPEG). Rose bengal (RB) was used as a model drug for encapsulation into the nanoparticles either during the particle production or by adsorption post particle preparation. The drug incorporation and release was affected by the different production methods and the different polymer compositions. When RB was loaded in HSA and HSA/HSA-PTAAC-PEG nanoparticles, up to 5% (w/w) drug content was achieved. The drug loading in HSA-mPEG nanoparticles was much lower and the results from the microcalorimetry study indicated that the low loading efficiency was due to less drug-protein binding sites available in the HSA-mPEG molecule as compared to the HSA molecule. The release of RB from the albumin nanoparticles was very slow in PBS and dramatically accelerated in the presence of trypsin. Compared with unmodified nanoparticles, the slower release of RB from the surface-modified HSA nanoparticles in the presence of the enzyme suggested that the existence of a steric hydrophilic barrier on the surface of the nanoparticles made digestion of the nanoparticles more difficult.
表面改性白蛋白纳米颗粒由两种聚乙二醇 - 人血清白蛋白共轭物制备而成:聚(硫醚酰胺酸)-聚乙二醇共聚物接枝的人血清白蛋白(HSA - PTAAC - PEG)和甲氧基聚乙二醇接枝的人血清白蛋白(HSA - mPEG)。孟加拉玫瑰红(RB)用作模型药物,在颗粒制备过程中或颗粒制备后通过吸附被包封到纳米颗粒中。药物的掺入和释放受不同生产方法和不同聚合物组成的影响。当RB负载在HSA和HSA/HSA - PTAAC - PEG纳米颗粒中时,药物含量可达5%(w/w)。HSA - mPEG纳米颗粒中的药物负载量要低得多,微量热法研究结果表明,与HSA分子相比,HSA - mPEG分子中可用的药物 - 蛋白质结合位点较少,导致负载效率较低。在PBS中,RB从白蛋白纳米颗粒中的释放非常缓慢,而在胰蛋白酶存在下则显著加速。与未改性的纳米颗粒相比,在酶存在的情况下,RB从表面改性的HSA纳米颗粒中释放较慢,这表明纳米颗粒表面存在空间亲水性屏障,使得纳米颗粒更难被消化。